EUVIMEDEUVIMED entdecken
Crossref

Skull Dosimetry for Mitigating Acute Hematologic Toxicity in Patients With Non-small Cell Lung Cancer With Brain Metastases Undergoing Cranial Radiation Therapy and Immunotherapy

Jiachun Ma, Hongxuan Yu, Xiao Zhang, Jupeng Yuan, Jinming Yu, Dawei Chen

International Journal of Radiation Oncology*Biology*Physics · 2026-07 · 125 (3) · 906-918

DOI: 10.1016/j.ijrobp.2025.12.033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-07. Verfasst von Jiachun Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Lung Neoplasms, Cranial Irradiation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Postdoctoral Innovation Project of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Brain radiation therapy (RT) combined with immunotherapy is standard for patients with non-small cell lung cancer (NSCLC) with brain metastases. However, RT-induced hematologic toxicities (HTs) can cause treatment interruption and lymphopenia, potentially impairing immunotherapy efficacy. Because the skull bone marrow has recently been identified as a key hematopoietic site, this study evaluated the impact of skull RT dose on HTs in patients with NSCLC undergoing cranial RT and immunotherapy. METHODS AND MATERIALS: This retrospective study consecutively included 191 patients with NSCLC with brain metastases treated between June 2018 and April 2023. Stereotactic RT or whole-brain RT was selected based on lesion characteristics. All doses were converted to equivalent 2-Gy fractions (EQD2). HTs were graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0. Skull dosimetric parameters (DmeanEQD2, V5EQD2 - V50EQD2) were analyzed for associations with grade ≥ 3 HTs (HT3+) using logistic regression. Normal tissue complication probability models and optimal cutoff thresholds were derived using logistic and receiver operating characteristic analyses. Based on these cutoffs, post-RT absolute lymphocyte count (ALC) and immunotherapy response rates were assessed in stratified groups. RESULTS: HT3+ occurred in 18.8% (36/191) of patients, with neutropenia (18.9%), leukopenia (15.2%), and lymphopenia (15.7%) being most frequent. Multivariate analysis, adjusting for age and other covariates, revealed significant associations between HT3+ and DmeanEQD2 as well as V5EQD2 -V20EQD2 (all P < .05). The normal tissue complication probability models predicted a 50% probability of HT3+ at the following thresholds: DmeanEQD2 = 41.3 Gy, V5EQD2 = 94.6%, V10EQD2 = 86.0%, and V20EQD2 = 77.0%. Receiver operating characteristic analysis identified optimal HT3+ cutoffs of DmeanEQD2≥ 32.2 Gy, V5EQD2≥ 82.0%, V10EQD2≥ 64.7%, and V20EQD2≥ 53.4%. Patients above these thresholds had over twice the HT3+ risk, significantly lower post-RT ALC, and reduced immunotherapy response rates (all P < .05), with higher post-RT ALC predicted better response. CONCLUSIONS: Higher skull radiation doses significantly increase severe HTs in patients with NSCLC receiving cranial RT and immunotherapy. Incorporating skull dose constraints may mitigate HTs, preserve lymphocytes, and enhance immunotherapy efficacy, warranting validation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungBrain NeoplasmsLung NeoplasmsCranial IrradiationSkullImmunotherapyHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAged, 80 and overLymphopeniaRadiotherapy DosageAdultROC CurveLymphocyte Count

Autor:innen und Institutionen

  • Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, and Shandong Academy of Medical Sciences, Jinan,…

Förderung

  • Natural Science Foundation of Shandong Province
  • Postdoctoral Innovation Project of Shandong Province
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

Ma, J., Yu, H., Zhang, X., Yuan, J., Yu, J., & Chen, D. (2026). Skull Dosimetry for Mitigating Acute Hematologic Toxicity in Patients With Non-small Cell Lung Cancer With Brain Metastases Undergoing Cranial Radiation Therapy and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics, 125(3), 906-918. https://doi.org/10.1016/j.ijrobp.2025.12.033

Vancouver

Ma J, Yu H, Zhang X, Yuan J, Yu J, Chen D. Skull Dosimetry for Mitigating Acute Hematologic Toxicity in Patients With Non-small Cell Lung Cancer With Brain Metastases Undergoing Cranial Radiation Therapy and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics. 2026;125(3):906-918. doi:10.1016/j.ijrobp.2025.12.033

BibTeX
@article{Ma2026,
  author = {Ma, Jiachun and Yu, Hongxuan and Zhang, Xiao and Yuan, Jupeng and Yu, Jinming and Chen, Dawei},
  title = {Skull Dosimetry for Mitigating Acute Hematologic Toxicity in Patients With Non-small Cell Lung Cancer With Brain Metastases Undergoing Cranial Radiation Therapy and Immunotherapy},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {125},
  number = {3},
  pages = {906--918},
  doi = {10.1016/j.ijrobp.2025.12.033}
}
Kostenlos starten →